ANDA 77590, held by Mylan. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 77590 (Galantamine Hydrobromide), held by Mylan, was first approved by FDA on May 29, 2009, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 2009 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE ยท tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 8MG BASE ยท tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 12MG BASE ยท tablet;oral | Galantamine Hydrobromide | Discontinued |
| Jun 28, 2023 | Supplement 13Labeling ยท Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Apr 28, 2016 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Nov 10, 2015 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Nov 10, 2015 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| May 29, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters